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INTRODUCTION 
 
 
  “GROWTH FOR THE SAKE OF GROWTH IS THE IDEOLOGY OF CANCER 
CELLS”  
                                                                                                          - Edward abbey                                      
       Breast cancer is a devastating illness both physically and emotionally 
for tens of thousands of women around the world.  The morbidity and 
mortality of breast cancer make it a leading cause of death in women aged 
35 to 55 years1.  It accounts for 33% of all female cancers and is responsible 
for 20% of cancer related death in women2, 3. 
              In India breast cancer ranks second to cancer cervix4. But it is 
proportionally on the increase.   In the metropolitan areas of India they 
appear to be relatively on the increase due to late marriage,  birth of the first 
child at a later age, and short period of breast feeding which are common 
practices among educated urban women4.  As facility of screening in India is 
mostly limited, 2/3rd of cancers detected are locally advanced disease5. 
     Locally advanced breast cancer encompass a heterogenous group of 
patient that includes those with a neglected slow growing tumour as well as 
those with aggressive disease.  LABC is relatively uncommon presentation 
in developed world accounting for only 5 to 20%.  But in the developing 
world like India it constitutes about 50% of the cases. 
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           Aggressive local treatment such as surgery or radiotherapy did little 
to improve the survival rates, but resulted in increased complications6, 7, 8, 9.  
Predominant pattern of failure in LABC is development of distant  
metastasis . With the development of systemic therapy to address 
micrometastasis, chemotherapy is routinely incorporated in the treatment of 
LABC6, 7, 8, 9. It can be given preoperatively/post operatively 
          Neoadjuvant chemotherapy is the primary chemotherapy given to 
patient prior to surgery or radiotherapy.  This has been used for treatment of 
Locally advanced breast cancer.  With development and testing of 
increasingly effective agents particularly anthracyclines, dramatic responses 
had been seen in significant proportion of patients10, 11.  Thus leading to 
interest in breast conservation12, 13 treatment in larger tumours and to the use 
of neoadjuvant chemotherapy in less advanced operable breast cancer. 
        Neoadjuvant chemotherapy is said to have a number of theoretical and 
practical advantages in treatment of LABC probably including10, 11, 12, 13 
- Early treatment of Micrometastasis 
- Limiting the rapid growth of metastatic foci after removal of primary 
tumour. 
- Decreased emergence of chemoresistant clones. 
- Extension of BCT to more patients with larger tumours. 
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Perhaps greatest potential advantage of the approach is opportunity to 
observe clinical responses to treatment and to assess the effect by 
pathological examination of surgical specimen. Further more if 
clinical/pathological response of primary tumour to neoadjuvant 
chemotherapy correlates with or predicts the response of metastasis and the 
prognosis of the patient such as overall survival14, it could greatly accelerate 
progress in designing newer treatment. 
 
    Though neoadjuvant CT in the treatment of LABC had been used in 
clinical trials for the past 2 decades in the developing world, not many 
studies have been conducted in developing countries like ours, where LABC 
constitutes about 50% of cases.  Hence this study was planned to evaluate 
the clinico/pathological response to Neoadjuvant CT in the treatment of 
LABC. 
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AIM OF STUDY 
    The role of adjuvant chemotherapy in the management of LABC showed 
significant improvement in progression free and overall survival rates.  
Conventionally adjuvant systemic CT is administered after local treatment in 
LABC.  However since introduction of conservative treatment modalities, 
there has been considerable interest in the efficacy of preoperative 
chemotherapy. Neoadjuvant CT is said to decrease tumor size there by 
helping in breast conservation treatment modalities. 
 
Therefore logical next step was to plan a study with the following objectives.  
1. To evaluate the clinical/pathological response of primary tumour and 
lymph node to preoperative chemotherapy (CAF regimen) 
2. To assess the relationship between patient outcome and tumor 
response to chemotherapy. 
3. To study whether preoperative chemotherapy permits breast 
conservation by reducing tumour size 
4. To assess the tumour involvement of resected margin.      
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REVIEW OF LITERATURE 
 
 
Embryology of the breast:32 33 
                 At the fifth of the sixth week of the fetal development, two 
ventral bands of thickened ectoderm (mammary ridge) are evident in the 
embryo. In most mammals paired breasts develop along these ridges which 
extend from the base of the forelimb to the region of the hind limb. These 
ridges are not prominent in human embryos and disappear after a short time, 
except for small portions that persist in the pectoral region.Each breast 
develops when an ingrowth of ectoderm forms a primary tissue bud in the 
mesenchyme.  The primary bud inturn  initiates the development of 15 to 20 
secondary buds.  Epithelial cords develop from the secondary buds and 
extend into the surrounding mesenchyme.  Major ducts open into shallow 
mammary pits, the proliferation of mesenchyme transforms the mammary 
pit into nipple.(Ref 9). 
 
Functional anatomy32 33 
 
             Breast is composed of 15 to 20 lobes which are each composed of 
several lobules.  Fibrous bands of connective tissue, travel through the breast 
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and insert perpendicularly into the dermis.  It is called the suspensory 
ligaments of Cooper.   It provides structural support.  The mature female 
breast extends from the level of infra mammary fold at the sixth or seventh 
rib. It extends transversally from the lateral border of the sternum to the 
anterior axillary line.  The deep surface of the rest on the fascia of the 
pectoralis major, serratus anterior, external oblique abdominis, and the upper 
part of the rectus sheath.  Axillary tail of Spence extends laterally across the 
anterior axillary fold.  The upper outer quadrant of the breast contains 
greater volume of the tissue than the other quadrant.  
 
Nipple areola complex. 
               The epidermis of the nipple areola complex of the breast is 
pigmented and variably corrugated, during puberty the pigment become 
darker and the nipple assumes an elevated configuration.  During pregnancy 
the areola enlarges and the pigment becomes further enhanced.  The areola 
contains sebaceous glands, sweat glands, accessory glands.  Dermal papillae 
at the tip of the nipple contains sensory nerve endings and meissner’s 
corpuscles. Smooth muscle bundle fibres which lie circumferentially and 
longitudinally along the major ducts, are responsible for the nipple erection.   
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Blood supply of the breast.37  40 
            Breast receives its blood supply from  
1) perforating branch of the internal mammary artery 
2) Lateral branch of posterior intercostals arteries 
3) Branches from the axillary artery including the lateral thoracic and 
pectoral branches of the thoraco acromial artery. 
    The second , third and the 4th anterior intercostals perforators and the 
branches of the internal mammary artery arborize as medial mammary 
artery. The lateral thoracic artery give rise to lateral mammary branches.  
The veins of the breast and the chest wall follow the course of the artery 
with the venous drainage being towards the axilla.  The 3 principal groups of 
veins are perforating branches of  
1) internal thoracic vein 
2) posterior intercostals veins 
3) axillary veins 
 
The vertebral plexus of veins (Batson’s plexus)34 35 36: It provides second 
route for spread of breast carcinoma via veins.  This venous plexus 
surrounds the vertebra and extends from the base of the skull to the 
sacrum.  Venous channels exist between  this plexus and the veins 
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associated with thoracic, abdominal and pelvic organ.  These veins do not 
have valves, making it possible for blood to flow through them in either 
direction.  This venous communication is of particular importance in the 
breast as the posterior intercostals arteries are in direct continuity with 
the vertebral plexus.  This potential pathway explains the metastasis of 
breast cancer to the vertebrae, skull, pelvic bone, and the CNS when 
there is no pulmonary metastasis. 
 
Innervation of the  breast.41 
                         Lateral cutaneous  branches of third through the 6th 
intercostals nerve provides sensory inervation of the breast and of the 
anterolateral chest wall.  Anterior branch of the supraclavicular nerve 
supplies a limited area of the skin over the upper portion of the breast.   
 
Lymphatic drainage of the breast.38 39 
                The boundaries for the lymphatic drainage of the axilla are not 
well demarcated, and there is considerable variation in the position of the 
axillary lymph node.  Six axillary lymph node groups recognized by 
surgeons 
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1) Axillary vein group (lateral group)- consist of 4 to 6 lymph nodes , 
lies medial to the vein and receives most of the lymph drainage from 
the upper extremity.  
2) External Mammary group: (Anterior or pectoral group) : consist of 5 
to 6 lymph nodes , lies along the lower border of pectoralis minor 
muscle contiguous with the lateral thoracic vessels.  It receives most 
of the lymph drainage from the lateral aspect of the breast. 
3) Scapular group:  (Posterior or subscapular) It consists of 5 to 7 lymph 
nodes lie along the posterior wall of the axilla at the lateral border of 
the scapula, contiguous with the subscapular vessels.  It receives 
lymph drainage from the lower posterior neck, posterior trunk and 
posterior shoulder.   
4) Central Group: It consists of 3 to 4 lymph nodes embedded in the fat 
of axilla lying immediately posterior to the pectoralis minor muscle. It 
receives lymph drainage from the axillary vein, external mammary, 
and scapula and directly from the breast.   
5) Sub clavicular group( Apical):  It consists of 6 to 12 lymph nodes 
lying  posterior and superior to the upper part of the pectoralis minor 
muscle.  It receives lymph drainage from all other group of axillary 
lymph node.   
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6) The interpectoral group:  (Rotter’s ) It consists of 1 to 4 lymph nodes, 
interposed between the pectoralis major and minor muscle.  It receives 
lymphatic drainage directly from the breasts.  From interpectoral 
group of lymphnodes lymph fluid  passes directly to the central and 
subclavicular group of lymphnodes. 
  Surgeons also define the axillary lymphnodes with the respect 
to their relationship with the pectoralis minor muscle.Lymph nodes that 
are located lateral to and below the lower border of the pectoralis minor 
are called the level 1.  It consists of external mammary, axillary vein and 
scapular group of lymph nodes.  Those lymph nodes located deep or 
posterior to the pectoralis minor muscle are called level 2.  It includes 
central  and interpectoral group of lymph nodes.  Lymph nodes located 
medial or above to the upper border of the pectoralis minor is called level 
3 nodes.  It includes subclavicular growth.  
Lymph flow: The plexus of lymph vessels in the breast arises in the inter 
lobular connective tissue and in the walls of lactiferous ducts, and 
communicates with the sub areolar plexus of lymph vessels.  Efferent lymph 
vessels from the breast pass around the lateral edges of pectoralis major 
muscle, and pierce the clavipectoral fascia ending in the external mammary 
group of lymph nodes.  Some vessels may travel directly to the scapular 
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group of lymph nodes .  From the upper part of the breast few lymph vessels 
pass directly to the sub clavicular group of lymph nodes.  Axillary lymph 
nodes usually receives more than 75% of the drainage from the breast.  The 
rest is derived primarily from the medial aspect of the breast, flows through 
the lymph vessels that accompany the perforating branches of the internal 
mammary artery and enters the internal mammary group of lymph nodes.  
Epidemiology and Natural history of breast Cancer : 
         The Breast Cancer is the most site specific cancer in women, and is the 
leading cause of death from cancer for women aged 40 to 45 years, It 
accounts for 33% of all female cancers and is responsible for 20% of the 
cancer related deaths in women.   
Natural History: Natural history of breast cancer is extremely complex and 
not fully understood.  There is wide spectrum of behaviour some cancers 
may disseminate very early and cause death even before primary is clinically 
apparent, where as the other patient may live for decades, and treated with 
indolent disease.  It is not uncommon to have recurrent disease 20 – 30 years 
after initial treatment, very young men tend to develop aggressive disease 
with less than 50% 5 year survival.   Bloom and colleagues described the 
natural history of breast cancers based on records of 250 women with 
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untreated breast cancers between 1805, and 1933.  The Median survival of 
population is 2.7 years after initial diagnosis.  
Etiology: Breast cancer is a heterogeneous disease with no single 
characterized  
cause.  
Epidemiological studies have identified many risk factors that increase the 
chance for a woman to develop breast cancer:  
• Factors with relative risk greater than 4  
o Advanced age  
o Being born in North America or northern Europe  
o High premenopausal blood insulinlike growth factor (IGF)–1 
level  
o High postmenopausal blood estrogen level  
o History of mother and a sister with breast cancer 
 
• Factors associated with a relative risk of 2-4  
o High socioeconomic status  
o Age at first full-term pregnancy older than 30 years  
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o History of cancer in one breast  
o Any first-degree relative with a history of breast cancer  
o History of a benign proliferative lesion, dysplastic 
mammographic changes, and a high dose of ionizing radiation 
to the chest 
 
• Factors associated with a relative risk of 1.1-1.9  
o Nulliparity  
o Early menarche (age <11 y)  
o Late menopause (age >55 y)  
o Postmenopausal obesity  
o High-fat diet/saturated fat–rich diet  
o Residence in urban areas and northern United States  
o White race - Older than 45 years  
o Black race - Younger than 45 years  
o History of endometrial or ovarian cancer 
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• Identified factors with a protective role against breast cancer  
o Age at first period older than 15 years  
o Breastfeeding for longer than 1 year  
o Monounsaturated fat–rich diet  
o Physical activity  
o Premenopausal obesity 
Genetic factors  
As with other cancers, breast cancer is the result of multiple genetic changes 
or mutations. Early mutations may be inherited (eg, mutations of breast stem 
cells) or acquired (eg, somatic mutations due to ionizing radiation, chemical 
carcinogens, or oxidative damage).  
Estrogens, by their proliferation-promoting effect on the breast epithelium 
later, increase the chance of DNA replication errors leading to carcinogenic 
mutations. Indeed, the common denominator to many of these risk factors is 
their effect on the level and duration of exposure to endogenous estrogenic 
stimulation.  
Early menarche, regular ovulation, and late menopause increase lifetime 
exposure to estrogens in premenopausal women, while obesity and hormone 
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replacement therapy increase estrogen levels in postmenopausal women. 
Conversely, late menarche, anovulation, and early menopause (spontaneous 
or induced) are protective, owing to their effect on lowering the level or 
shortening the duration of estrogenic exposure.  
Lactation and premenopausal obesity are associated with lower estrogen 
levels as a result of anovulation. For unknown reasons, pregnancy decreases 
breast tissue susceptibility to somatic mutations; thus, the earlier the first 
pregnancy, the shorter the susceptibility period.  
Hereditary breast cancers have been thought to represent a small proportion 
(5-10%) of all breast cancers. However, based on new data derived from the 
comparison of identical and nonidentical twins, up to 27% of breast cancers 
may be attributed to inherited factors. The mutated genes BRCA1 and 
BRCA2 are responsible for approximately 30-40% of inherited breast 
cancers.  
The prevalence of BRCA1 in the general population is 0.1%, compared with 
20% in the Ashkenazi Jewish population. The gene is encountered in 3% of 
the unselected breast cancer population and in 70% of women with inherited 
early-onset breast cancer. Up to 50-87% of women carrying a mutated 
BRCA1 gene develop breast cancer during their lifetime.  
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Risks for ovarian and prostate cancers are also increased in carriers of this 
mutation. BRCA2 mutations are identified in 10-20% of families at high risk 
for breast and ovarian cancers and in only 2.7% of women with early-onset 
breast cancer. The lifetime risk of developing breast cancer in female 
carriers is 25-30%. BRCA2 is also a risk factor for male breast cancer; 
carriers have a lifetime risk of 6% for developing the cancer. BRCA2 
mutations are associated with other types of cancers, such as prostate, 
pancreatic, fallopian tube, bladder, non-Hodgkin lymphoma, and basal cell 
carcinoma.  
Li-Fraumeni syndrome, characterized by a mutation of TP53, is associated 
with multiple cancers, including the SBLLA syndrome (sarcoma, breast and 
brain tumors, leukemia, laryngeal and lung cancer). Cancer susceptibility is 
transmitted by an autosomal dominant pattern, with penetrance 
approximating 90% by age 70 years. Li-Fraumeni syndrome is identified in 
1% of women with early-onset breast cancer. Bilateral breast cancer is noted 
in up to 25% of patients.  
Cowden disease is a rare genetic syndrome associated with papillomatosis of 
the lips and oral mucosa, multiple facial trichilemmomas, and acral 
keratosis. The prevalence rate of breast cancer in women with this disease is 
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29%. Benign mammary abnormalities (eg, fibroadenomas, fibrocystic 
lesions, ductal epithelial hyperplasia, nipple malformations) are also more 
common. Other rare genetic disorders, such as Peutz-Jeghers and Muir-Torre 
syndromes, are associated with an increased risk of breast cancer.  
Lab Studies:  
• CBC count with differential and platelet count 
• Chemistry and renal function studies 
• Liver function tests 
• Calcium and phosphorus evaluations 
Imaging Studies:  
• Mammography: Bilateral study is necessary for screening, diagnosis, 
and follow-up care. Malignant and benign breast lesions have the 
following mammographic characteristics: 
o Malignant breast lesions  
 Irregular speculated mass  
 Clustered calcifications  
 Calcifications - Smaller than 0.5 mm in diameter  
 Architectural distortion  
 Focal asymmetric density 
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o Benign breast lesions  
 Solid- or lucent-centered spheres  
 Smooth and round calcifications  
 Calcifications - Larger than 1 mm in diameter  
 Architectural distortion - Usually not present 
• Chest radiograph 
• CT scan of the brain, chest, abdomen, and pelvis:  if the patient has 
neurologic symptoms, abnormal chest radiograph results, 
supraclavicular lymphadenopathy and hepatosplenomegaly, or 
abnormal liver function test results. CT scan of   respective part done 
• Bone scan:  a bone scan is done if any of the following conditions are 
present: 
o Advanced local disease 
o Lymph node metastases 
o Distant metastases 
o Bony symptoms 
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Other Tests:  
• Pathologic study of tumor specimens: Three features are evaluated 
and given scores from 1-3, ie, tubule formation, nuclear 
pleomorphism, and mitotic activity. 
o Tubular grade is defined based on the degree of development of 
tubular formations.  
 Well differentiated if tubular structures occupy more than 
75% of the tumor - 1 point  
 Moderately differentiated if tubular structures represent 
10-75% of the tumor - 2 points  
 Poorly differentiated if the tubular structures represent 
less than 10% of the tumor - 3 points 
o The nuclear grade is defined based on the nucleus size, stain 
density, and shape variations.  
 Small and uniformly staining nucleus, good prognosis - 1 
point  
 Moderate variation in nuclear size and shape, 
intermediate prognosis - 2 points  
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 Marked nuclear polymorphism with dark staining, poor 
prognosis - 3 points 
o Determine the cycling fraction (mitotic index and S-phase). 
While  the determination of the S-phase requires the use of flow 
cytometry, the mitotic index is the easiest and fastest way of 
assessing proliferation. Score the mitotic index as follows:  
 Low (0-3.3/mm2) - 1 point  
 Medium (3.3-7/mm2) - 2 points  
 High (>7/mm2) - 3 points 
o The histologic grade is a composite index obtained by totaling 
the tubular, nuclear, and mitotic scores. Invasive breast cancer 
is graded as follows:  
 Well differentiated - 3-5 total points  
 Moderately differentiated - 6-7 total points  
 Poorly differentiated - 8-9 total points 
• ER and PR evaluation: Two types of assays are used to quantitate ERs 
and PRs. 
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o For ligand-binding methods (eg, dextran-coated charcoal 
assay), results are expressed in femtomoles of receptor protein 
per milligram of cytosol protein (fmol/mg). Cutoffs vary from 
3-20 fmol/mg, depending on the laboratory. To ensure accuracy 
and reproducibility, specimens should be large and must be 
immediately fixed in liquid nitrogen. Results of this method 
may be affected by the presence of estrogens or tamoxifen in 
the specimen. 
o With regard to monoclonal antibody–based methods (eg, 
immunohistochemistry [IHC], enzyme immunoassay), IHC has 
2 advantages. First, it can be performed on any type or size of 
specimen, including cell blocks from body fluids or those fixed 
or imbedded in paraffin. Second, it measures total protein; 
therefore, it is not affected by the presence of estrogens or 
tamoxifen. IHC is a semiquantitative technique that depends on 
the observer and the type of antibodies used. Enzyme 
immunoassay results are more objective because of the use of a 
spectrophotometer to quantitate the receptor protein; however 
the technique is limited by the need for a sufficiently large 
fresh, frozen specimen. 
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• HER2/neu status: Several methods have been used to detect and 
quantitate HER2/neu. 
o IHC methods have been extensively used. This method is a 
semiquantitative assay using a monoclonal antibody. 
o Scoring of HER2/neu overexpression using the DAKO 
HercepTest (DAKO Cytomation; Carpinteria, Calif) follows. 
The cell membrane staining pattern, the interpretation, and the 
score are listed.  
 Strong complete membrane staining in more than 10% of 
tumor cells - Interpreted as strongly positive; score of 3+  
 Weak-to-moderate complete membrane staining in more 
than 10% of cells - Interpreted as weakly positive; score 
of 2+  
 Faintly perceptible membrane staining in more than 10% 
of tumor cells - Interpreted as negative; score of 1+  
 No staining or staining in 10% of tumor cells - 
Interpreted as negative; score of 0  
 Cytoplasmic staining of any intensity - Interpreted as 
negative; score of any 
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o Detection of gene amplification with fluorescence in situ 
hybridization (FISH) is highly specific and has an 82% overall 
concordance rate with IHC. However, when FISH results are 
expressed in the function of the IHC scores, they are positive in 
92% of 3+ and 39% of 2+ IHC specimens. Only 7% of 1+ IHC 
specimen results are FISH-positive. 
o Certain authorities consider FISH to be the criterion standard 
for HER2/neu evaluation; however, because this test is not 
readily available in many laboratories, they recommend use of 
IHC as a first-line test; 3+ and 1+ IHC results correspond to 
positive and negative expression of HER2/neu, respectively, 
and a 2+ IHC result is considered borderline. In these cases, 
only FISH is performed because a significant number of true 
HER2/neu–positive patients may be identified in the 2+ IHC 
group. 
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Diagnostic Procedures:  
• Surgical procedures for nonpalpable lesions 
o Image-guided core-needle biopsy  
 This is the preferred method for needle biopsy of a 
nonpalpable lesion. Because of sampling error, it carries 
a higher risk of false-negative findings than open biopsy. 
Negative or equivocal results in the face of suggestive 
mammogram findings or residual calcifications should be 
followed by an open biopsy. False-negative results are 
encountered in 1-10% of biopsies, with the highest rates 
occurring with the least-experienced operators.  
 For the technique, ultrasound is the method of choice to 
guide the core-needle biopsy. Stereotactic 
mammographic guidance is used in lesions not visualized 
on ultrasound images. Stereotactic core-needle 
techniques have the advantages of lower complication 
rates and lower costs, although they cannot be used when 
the lesion is very close to the chest wall or areola, where 
open biopsy is the best approach. The radiograph should 
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be compared with the mammogram to ensure that all 
calcifications are included within the core biopsy 
specimen.  
o Open biopsy with needle localization  
 Invasive localization techniques with small radiopaque 
needles to guide a surgical biopsy are used more 
commonly than noninvasive techniques.  
 For the technique, local anesthesia with or without 
intravenous sedation is sufficient in most cases. A thin 
needle and a fine wire with a thickened distal segment 
are used for immediate preoperative localization of the 
lesion. The incision may include the wire entry site if the 
lesion is superficial. A core of tissue along and around 
the wire is excised (including the lesion easily identified 
by the previous placement of the thickened segment 
inside it) and sent en bloc for radiographic evaluation. 
However, when the wire entry site is located far from the 
lesion, the incision should be placed directly over the 
lesion; dissection is then performed to find the wire.  
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 Once identified, the free end of the wire is pulled up 
through the incision. A core of tissue around the wire is 
excised (including the lesion) and sent for radiographic 
evaluation. Closure should not proceed until radiographic 
confirmation that the entire lesion was excised. 
• Surgical procedures for palpable lesions 
o Fine-needle aspiration biopsy  
 In experienced hands, FNA biopsy may provide a high 
accuracy rate when combined with physical examination 
and mammography (sensitivity ~80-98%, specificity 
~100%). However, negative results from a palpable 
lesion cannot exclude carcinoma. Lesions most suited for 
this procedure are T3 and T4 tumors and axillary or chest 
wall relapses.  
 Owing to the high false-negative rate with FNA in 
lesions smaller than 1 cm in diameter, another diagnostic 
procedure should be used. Because false-positive rates 
are extremely low (<2%), positive results are sufficient to 
plan surgery, without the need for further investigation. 
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However, perioperative frozen sections are necessary to 
distinguish between invasive and in situ carcinoma and to 
determine the need for axillary dissection because FNA 
results cannot be used to make this distinction.  
o Cutting-needle (core-needle) biopsy  
 Although the cutting-needle biopsy technique is 
associated with a higher true-positive rate than the FNA 
technique, a negative result may reflect sampling error. 
This biopsy provides a cylinder of tissue for pathological 
rather than cytological analysis. Determination of ERs 
and PRs is possible. Its best indications are large tumors 
and chest wall relapses. Small lesions or those 
surrounded by fibrocystic tissue are better studied using 
FNA. .  
o Excision (open) biopsy  
 The entire lesion is removed with excisional biopsy, 
along with a margin of normal breast tissue.  
 Local anesthesia, occasionally with intravenous sedation, 
is sufficient to perform most of these procedures. A 
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curvilinear incision should be placed directly on the 
tumor mass and oriented in such a way that it could be 
included within a future mastectomy incision. In 
extremely lateral or medial lesions, a radial incision 
placed over the lesion is preferable.  
 Once the tumor is removed, the margins should be inked. 
After hemostasis is achieved, deep breast tissue 
approximation is performed only if this does not result in 
deformity of the breast contour. Lastly, the skin is closed 
with a subcuticular closure.  
o Incisional biopsy: This is indicated for lesions 4 cm or larger 
and whenever neoadjuvant chemotherapy or RT is 
contemplated. 
Histologic Findings: The various histopathologic types are as follows:  
• I - Ductal  
o Intraductal (in situ)  
o Invasive with predominant intraductal component: Infiltrating 
or invasive ductal cancer is the most common breast cancer 
histologic type, comprising 70-80% of all cases.  
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o Invasive, not otherwise specified  
o Scirrhous  
o Tubular  
o Medullary with lymphocytic infiltrate  
o Mucinous (colloid)  
o Papillary  
o Inflammatory  
o Comedo  
o Other 
• II - Lobular  
o In situ  
o Invasive with predominant in situ component  
o Invasive 
• III - Nipple  
o Paget disease, not otherwise specified  
o Paget disease with intraductal carcinoma  
o Paget disease with invasive ductal carcinoma 
• IV - Undifferentiated carcinoma  
• V - Rare tumor subtypes: The following are not considered typical 
breast cancers.  
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o Cystosarcoma phyllodes  
o Angiosarcoma  
o Primary lymphoma 
In situ carcinoma  
In situ carcinoma is characteristically contained within the epithelium, with 
the basement membrane intact, and no signs of invasion. Many features 
distinguish lobular carcinoma in situ (LCIS) from DCIS.  
LCIS arises from the terminal duct lobular apparatus and shows a rather 
diffuse distribution throughout the breast, without evidence of a palpable 
mass. DCIS originates from the major lactiferous ducts and tends to be a 
localized disease frequently associated with a palpable mass.  
This explains the high incidence of synchronous involvement in the 
contralateral breast (bilaterality) or in other quadrants of the same breast 
(multicentricity) in LCIS (90-100%) compared with DCIS (10-15%), 
suggesting that complete surgical resection of DCIS is not only possible but 
also desirable, particularly if the index lesion manifests as a palpable mass. 
Conversely, locoregional modalities, such as surgery or RT, have no role in 
the treatment of LCIS except for prophylactic bilateral mastectomy.  
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DCIS originates by proliferation of the ductal luminal cells, which form 
protrusions into the lumen (papillary DCIS). These become more coalescent, 
leaving a few empty, rounded spaces (cribriform DCIS). When the lumen is 
filled with proliferating cells, it becomes completely obliterated (solid 
DCIS). Central areas of these ducts undergo necrosis because of the 
ischemic microenvironment (comedo DCIS), with secondary deposition of 
calcium responsible for the appearance of microcalcifications, a typical 
radiographic feature of this disease.  
DCIS is probably a continuum of successive steps of the same process, with 
increasing malignant potential as the disease progresses from papillary to 
comedo forms. Indeed, cells in the earliest stages are well differentiated with 
no atypia or mitoses, while cells in advanced stages become more anaplastic 
with frequent mitotic figures.  
From a practical standpoint, dividing DCIS into 2 categories, comedo-type 
and non–comedo-type, is helpful. Both DCIS and LCIS occasionally may be 
difficult to differentiate from atypical hyperplasia (eg, atypical ductal 
hyperplasia, atypical lobular hyperplasia), which is a benign change of the 
mammary gland preceding the in situ disease.  
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• Local recurrence  
o Comedo - High  
o Noncomedo - Low 
• Prognosis  
o Comedo - Poor  
o Noncomedo - Good 
Invasive ductal carcinoma develops in 30-50% of patients with DCIS over a 
10-year period, usually in the same quadrant where the DCIS was found. In 
contrast, only 10-37% of patients with LCIS develop invasive carcinoma, 
mostly of the ductal variety and with equal frequency in both breasts. 
Therefore, DCIS may be considered a true precancerous process, while 
LCIS is only a marker of increased risk for cancer.  
Infiltrating ductal carcinoma with productive fibrosis (scirrhous, simplex, 
not otherwise specified) represents approximately 80% of ductal carcinoma 
of the breast cases, with the highest prevalence associated with 
perimenopause or early postmenopause. Typically, the mass is solitary, firm, 
and nontender with poorly defined borders. Heterogeneity is a characteristic 
feature of the malignant cells, which are arranged in single rows, producing 
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the so-called Indian filing. Typical sites of metastases are bone, lung, and 
liver.  
Medullary carcinoma is relatively uncommon (5-7%) and occurs in younger 
persons. It manifests as a bulky palpable mass, with axillary 
lymphadenopathy in 40% of patients. Microscopically, the tumor has a 
syncytial growth pattern, without tubuloglandular differentiation in 75% of 
the tumor, mixed with intense lymphoplasmacytic infiltrate and, in most 
cases, associated with reactive lymphadenopathy. Nuclei are large and 
pleomorphic (grade 2 or 3). DCIS may be observed in the neighboring 
normal tissues, although there is no increased risk of bilaterality or 
multicentricity. ER, PR, and HER2/neu are usually negative and TP53 is 
commonly mutated. The prognosis of patients with this type is usually very 
good.  
Mucinous carcinoma is another uncommon histologic type of invasive breast 
cancer (<5%). It is more common in the seventh decade of life and manifests 
clinically as a palpable mass or mammographically (with increasing 
frequency) as a poorly defined tumor with rare calcification. Its histologic 
hallmark is the presence of mucin production occupying more than 90% of 
the tumor in pure mucinous forms and variable percentages in the mixed 
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forms. The cells are clustered in small islets dispersed in a pool of mucin. 
DCIS is often present in the vicinity of the tumor. ERs and PRs are positive 
in 90% and 68% of cases, respectively. HER2/neu overexpression is 
extremely rare. Patients with pure mucinous carcinoma have a better 
prognosis than those with mixed forms or other breast cancers of no special 
type.  
Inflammatory breast cancer is diagnosed clinically based on the association 
of edema, erythema, and skin ridging (peau d'orange). Although subdermal 
lymphatic and vascular invasion is nearly constant, it is not a mandatory 
criterion for diagnosis. The mass is not palpable in most cases. Molecularly, 
ERs and PRs are negative, HER2/neu is overexpressed, TP53 is commonly 
mutated, and the thymidine-labeling index is frequently high. Inflammatory 
carcinoma is an aggressive but fortunately rare disease, with a sudden onset 
and a rapidly progressive course. It is uniformly fatal if not treated with 
multimodality therapy. It should be differentiated from benign cellulitis by 
the characteristic absence of polymorphonuclear leukocytes in the involved 
area and from locally advanced breast cancer with a secondary inflammatory 
component, which has a more indolent course and is often responsive to HT. 
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 Lobular carcinoma  
Invasive lobular carcinoma is the second most common histologic type after 
ductal carcinoma, accounting for 5-10% of all breast cancers. It is associated 
with a high rate of multifocality and bilaterality. LCIS is identified in 70-
80% of cases. It may manifest as a palpable mass clinically and 
mammographically indistinguishable from ductal carcinoma, except that the 
extent of the tumor is often underestimated in lobular carcinoma. Typical 
lobular carcinoma is composed of small, homogenous cells that invade the 
stroma in a single-file pattern. Signet-ring cells may be observed. Their 
stromal desmoplastic reaction is mild or absent. While ERs and PRs are 
expressed in the majority of tumors, HER2/neu overexpression and TP53 
mutation are rare.  
Tumor behavior is characterized by more common bone metastases and less 
frequent lung, liver, and brain metastases than ductal carcinoma. Metastases 
to the leptomeninges, peritoneum, retroperitoneum, GI tract, and 
reproductive system seem to be more common in lobular carcinoma 
compared with ductal carcinoma. Patients with the classic form of lobular 
carcinoma share the same prognosis as those who have ductal carcinoma, 
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patients with the tubulolobular variant fare slightly better, and those with the 
signet-cell variant fare significantly worse than average 
Nipple  
Paget disease of the breast is a relatively rare entity comprising 
approximately 1% of all breast cancer cases, with the highest incidence in 
the seventh decade of life. However, pathologic evidence of the disease can 
be observed in 2-5% of mastectomy specimens. Approximately half the 
patients present with an underlying mass, which is an invasive cancer in 
93% and a DCIS in 7%. In patients with no mass upon presentation, invasive 
cancer is present in approximately 40% and DCIS in approximately 60%. 
Histologically, the disease is localized to the epithelium of the nipple-areola 
complex and the characteristic cells, or Paget cells, are contained within the 
basement membrane. Paget cells are large, pale cells with prominent nuclei 
and large nucleoli, dispersed between the keratinocytes as single or clusters 
of cells.  
Other  
Tubular carcinoma is an uncommon type with limited metastatic potential 
and a very good prognosis. The average size of pure tubular carcinomas is 
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smaller than 1 cm, and they are associated with axillary metastases in 
approximately 15% of cases. Mammographically detected tumors (60-70%) 
tend to be smaller and less frequently associated with nodal metastases than 
clinically detected tumors. Characteristic features of this type include a 
single layer of epithelial cells with low-grade nuclei and apical cytoplasmic 
"snoutings" arranged in well-formed tubules and glands. Tubular elements 
comprise more than 90% of pure tubular carcinomas and different 
proportions of mixed tubular tumors. DCIS is associated with most of these 
tumors. ERs and PRs are positive in 70-100% and 60-83%, respectively. 
HER2/neu overexpression and TP53 mutation are very uncommon in this 
type.  
Papillary carcinoma is rare (<1% of breast cancers), occurring mainly in 
postmenopausal women. Histologically, the tumor is circumscribed with 
cells arranged in delicate or blunt papillae. Nuclei are of intermediate grade. 
Occasionally, extracellular mucin production can be observed. ERs and PRs 
are positive in approximately 100% and 80% of cases, respectively. 
Lymphatic vessel invasion occurs in a third of the cases; however, axillary 
lymph node enlargement can be related to benign reactive changes in a 
significant number of cases. This type has a good prognosis. The papillae in 
the micropapillary type lack the lymphvascular core. This type is associated 
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with lower ER and PR positivity and a higher percentage of HER2/neu 
overexpression, which explain its worse prognosis.  
 
Staging: The American Joint Committee on Cancer staging system groups 
patients based on the tumor size (T), lymph node status (N), and distant 
metastases (M) into 4 stages, thus allowing clinicians to derive prognostic 
information necessary for therapeutic decisions. ER and PR status in the 
tumor tissue, menopausal status, and the general health of the patient are the 
other factors required for the final therapeutic plan.  
TNM definitions  
• Primary tumor 
o TX - Cannot be assessed  
o T0 - No evidence of primary tumor  
o Tis - Carcinoma in situ, intraductal carcinoma, LCIS, or Paget 
disease of the nipple with no associated tumor (Note: Paget 
disease associated with a tumor is classified according to the 
size of the tumor.)  
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o T1 - Tumor 2 cm or smaller in greatest dimension  
 T1mic - Microinvasion 0.1 cm or less in greatest 
dimension  
 T1a - Tumor larger than 0.1 cm but not larger than 0.5 
cm in greatest dimension  
 T1b - Tumor larger than 0.5 cm but not larger than 1 cm 
in greatest dimension  
 T1c - Tumor larger than 1 cm but not larger than 2 cm in 
greatest dimension  
o T2 - Tumor larger than 2 cm but not larger than 5 cm in greatest 
dimension  
o T3 - Tumor larger than 5 cm in greatest dimension  
o T4 - Tumor of any size with direct extension to (a) chest wall or 
(b) skin, only as described below (Note: Chest wall includes 
ribs, intercostal muscles, and serratus anterior muscle, but not 
pectoral muscle.)  
 T4a - Extension to chest wall  
 T4b - Edema (including peau d'orange) or ulceration of 
the skin of the breast or satellite skin nodules confined to 
the same breast  
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 T4c - Both of the above (T4a and T4b)  
 T4d - Inflammatory carcinoma (Note: Inflammatory 
carcinoma is a clinicopathologic entity characterized by 
diffuse brawny induration of the skin of the breast with 
an erysipeloid edge, usually without an underlying 
palpable mass. Radiologically, a detectable mass and 
characteristic thickening of the skin may be present over 
the breast. This clinical presentation is due to tumor 
embolization of dermal lymphatics with engorgement of 
superficial capillaries.) 
• Regional lymph nodes 
o NX - Cannot be assessed (eg, previously removed)  
o N0 - No regional lymph node metastasis  
o N1 - Metastasis to movable ipsilateral axillary lymph node(s)  
o N2 - Metastasis to ipsilateral axillary lymph node(s) fixed to 
each other or to other structures  
o N3 - Metastasis to ipsilateral internal mammary lymph node(s) 
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• Pathologic classification 
o pNX - Regional lymph nodes cannot be assessed (eg, not 
removed for pathologic study or removed previously)  
o pN0 - No regional lymph node metastasis  
o pN1 - Metastasis to movable ipsilateral axillary lymph node(s)  
 pN1a - Only micrometastasis (none >0.2 cm)  
 pN1b - Metastasis to lymph node(s), any larger than 0.2 
cm  
 pN1bi - Metastasis in 1-3 lymph nodes, any larger 
than 0.2 cm and all smaller than 2 cm in greatest 
dimension  
 pN1bii - Metastasis to 4 or more lymph nodes, any 
larger than 0.2 cm and all smaller than 2 cm in 
greatest dimension  
 pN1biii - Extension of tumor beyond the capsule 
of a lymph node metastasis, smaller than 2 cm in 
greatest dimension  
 pN1biv - Metastasis to a lymph node 2 cm or 
larger in greatest dimension  
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o pN2 - Metastasis to ipsilateral axillary lymph node(s) fixed to 
each other or to other structures  
o pN3 - Metastasis to ipsilateral internal mammary lymph node(s) 
• Distant metastasis 
o MX - Cannot be assessed  
o M0 - No distant metastasis  
o M1 - Distant metastasis present (includes metastasis to 
ipsilateral supraclavicular lymph nodes) 
• American Joint Committee on Cancer stage groupings 
o Stage 0 - Tis, N0, M0  
o Stage I - T1 (includes T1mic), N0, M0  
o Stage IIA  
 T0, N1, M0  
 T1 (includes T1mic), N1 (The prognosis of patients with 
pN1a disease is similar to that of patients with pN0 
disease.), M0  
 T2, N0, M0 
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o Stage IIB  
 T2, N1, M0  
 T3, N0, M0 
o Stage IIIA  
 T0, N2, M0  
 T1 (includes T1mic), N2, M0  
 T2, N2, M0  
 T3, N1, M0  
 T3, N2, M0 
o Stage IIIB  
 T4, Any N, M0  
                     Stage IIIC 
              Any T,N3, M 0 
  Stage IV-  Any T, Any N, M1 
LOCALLY ADVANCED BREAST CANCER 
           It includes heterogenous group of patients with a varying biology and 
a range of prognosis.  This group includes 
1) Tumor size of more than 5 cm with a mobile axillary node 
2) Tumour of any size with a fixed axillary node 
3) Ttumour of any size with the skin/chest wall fixity.   
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4) Tumour of any size with supraclavicular node. 
5) Inflammatory breast cancer. 
Incidence:2 Percentage of patients in stage IIIB is 8.1% in 1991.  10% of 
low income patients presented with stage III disease compared to 7% of 
the high income patients.  Stage III is diagnosed in approximately 13,000 
women annually making it still a major health problem. 
Historical Perspective: Haagensen and stout analysed 1135 cases of 
breast cancer treated with radical mastectomy during the period of 1915 
to 1942.  They identified 5 features of locally advanced breast cancer and 
called it as Grave sign.  It includes edema of less than 1/3 rd of the skin 
of the breast, Ulceration of the skin, fixation to the chest wall, fixed 
axillary node, and axillary node more than 2.5 cm. They have noted a 5 
year clinical cure, 5 to 38% of the LABC patients treated by radical 
mastectomy. Local recurrence ranged from 13 to 40%.  Baclesse 
observed 5 year survival rate for LABC was 30% , among the patient 
with LABC treated with primary radiation alone.  This observation 
suggested that LABC was systemic disease with micrometastasis present 
at the time of diagnosis.  Hence local therapy alone was insufficient to 
cure most patients  with this disease.  
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Prognostic factor : 
1) Size of the primary tumour: fisher and coworkers42 concluded that 
patients with tumours greater than 6 cms had a 63% of axillary nodal 
metastasis compared to 30% in patients with 1 to 2 cm tumours.   
There was direct relation ship of primary tumour size to the extent of 
axillary metastasis and tumour recurrence rate.  
2) Oestrogen receptor status: Steward and colleagues44 reported 
significant increase in the overall survival for operable LABC with 
positive estrogen receptor status. However in patients with inoperable 
breast carcinoma, estrogen receptor status had no effect on prognosis.   
3) Thymidine labeling index:  Silvestrini and coworkers45 observed that 
high labeling index was associated with high recurrence rate.  A short 
time to disease progression and low survival rate.  
 
Management of Locally advanced breast cancer. 
Surgery: Donegan49 reported a 50% local recurrence rate in patients with 
inoperable disease treated with surgery alone.  Fracchia observed survival 
rate of 21% in stage IIIA patients. It was clear that surgery alone was 
inadequate treatment. 
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Radiotherapy : Zucaly and colleagues51 reported 5 year survival rate of 30% 
in patients with LABC treated only with primary radiotherapy.  It could be 
concluded from the studies , large tumour burden was not treated adequately 
by radiation alone. 
 Surgery and Radiotherapy: Surgery followed by radiation resulted in local 
control rate of 70 to 86% and 5 year survival rate of 30 to 45 %  
 
Combined Modality Therapy: The Unimodality experiences demonstrated 
that good local control rates by surgery or radiotherapy alone did not 
correlate with good prognosis and ultimate survival. Hematogenous 
metastasis were not being controlled with either radical surgery or radical 
radiotherapy alone. In early 1970’s systemic chemotherapy was incorporated 
as integral part of primary management of LABC.  Grohn and coworkers53 
reported that 5 year disease free survival was 22% for those given 
radiotherapy and 30% for those given chemotherapy and 67% for those 
given multimodality treatment. (surgery followed bychemotherapy and 
radiotherapy) 
   Derman and coworkers 54observed patients who had received systemic 
treatment after surgery had significant increase in disease free survival, 
without increase in overall survival.   
  47
  Olson and colleagues,55 suggested combined modality of treatment resulted 
in fewer loco regional failure in LABC.  These randomized trials revealed 
that a modest increase in survival when chemotherapy was used in 
conjunction with local therapy. Local treatment alone did not affect overall 
survival.  So combined modality of treatment was the standard for the 
treatment of LABC. 
 
 PRIMARY CHEMOTHERAPY   or NEOADJUVANT CHEMOTHERAPY: 
 NSABP B- 18 study56 evaluating the role of primary chemotherapy, in 
women with operable breast cancer, showed that there was no significant 
difference in disease free or overall survival of those patients treated with 
primary chemotherapy followed by surgery and radiotherapy compared to 
patients treated with surgery, followed by chemotherapy and radiation.  
Eventhough there was no advantage of survival benefit in Neoadjuvant 
chemotherapy over adjuvant chemotherapy it had following benefits: 
1) Ability to convert the inoperable tumours to operable ones.   
2) Assessment of tumour response to chemotherapy in vivo.   
3) Chemotherapeutic ablation of primary tumour may alter the growth 
characteristics of residual metastasis. 
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4) Initial response to primary chemotherapy predicted the disease free 
and overall survival rate.   
Assessment of disease response to Neoadjuvant Chemotherapy  
 
Mammography: Maskowic and coworkers 46reported that clinical and 
mammographic findings were in concurrence in 79% of the patients.  Digital 
mammography had the capacity of achieving the spatial resolution of images 
as small as 1/20th of millimeter. It has the potential to detect areas of breast 
tissue that harbour the occult cancer. 
Ultrasonography: Powles and coworkers47 noted that there was better 
correlation of tumour shrinkage to clinical response on ultrasonography than 
on mammography.  Fornage and colleagues reported that sonographic 
measurement of established breast cancer correlated with pathological 
examination more closely than the mammographic measurement.   
Magnetic resonance imaging: A recently developed MRI technique for 
evaluating breast cancer had shown better pathological correlation than 
conventional imaging techniquies. This new MRI technique utilized a new 
pulse sequence called RODEO (ROTATING DELIVERY OF 
EXCITATION OFF-RESONANCE) that produced high-resolution images 
emphasizing the gadolinium contrast – enhancement qualities of cancers 
over the background tissues, including fat and normal breast parenchyma. 
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          In a study of 39 patients with locally advanced breast cancer receiving 
primary chemotherapy RODEO MRI was able to accurately predict the 
extent of residual disease in 30 of 31 cases reviewed (97%).48 
Clinical and histological  response: Feldman and coworkers reported 
that histological response more than the clinical response to primary 
chemotherapy was the single most important prognostic factor for both and 
disease free and overall survival rate in patients with LABC.  Although 
complete clinical response ranged from 5 to 66%, histological negative 
disease occurred only in 2 to 29%.  The following table summarizes various 
studies with complete clinical and histological responses.        
thor and year Treatment 
design 
No. of 
patients
Complete 
clinical 
response 
Complete 
histologic 
response 
Conte (1987)61 CT+S+RT 39 15 8 
Hortbagyi(1988)59 CT±S+RT+CT 174 17 8 
Hobar(1988)57 CT+S+RT+CT 36 8 11 
Cocconi(1990) CT+S+CT+RT 49 8 14 
Schwartz(1994)60 CT+S+RT+CT 189 8 10 
Bonadona(1995) CT+S+RT+CT 227 21 4 
Sataloff(1995)62 CT+S+CT+RT 36 33 39 
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Breast conservation in LABC  
There has been growing interest in breast conservation for patients with 
LABC, after the advent of Neoadjuvant Chemotherapy Jacquelet and 
coworkers63 reported that five years of overall survival rate and disease free 
survival rate of those patients who had undergone a breast conservation 
surgery was similar to those patients who had undergone Modified Radical 
Mastectomy.  Singletary and Coworkers observed none of the patients who 
underwent breast conservation surgery after neoadjuvant therapy had 
evidence of local reference.  Therefore it can be concluded that there was  a 
subset of  patients with a LABC who would be candidates for BCS 
following primary chemotherapy. 
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TREATMENT RECOMMENDATION FOR LABC 
 
                The  following is the treatment alogorithm for stage III Breast 
carcinoma  
 
                            Diagnosis and staging 
 
          Neoadjuvant chemotherapy 
                     ( 3 to 4 cycles) 
 
 
Responders                                                   Nonresponders 
                     
Surgical resection  
(BCT or MRM)                                            Operable                   Inoperable 
             
Adjuvant  Chemotherapy                           surgery             2nd line chemotherapy 
 
RADIOTHERAPY                                                                               Inoperable 
 
                                                                             radiotherapy 
          Operable 
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MATERIALS AND METHODS 
                                                                                                                                  
This study was carried out in the Department of Surgery, Government Rajaji 
Hospital Madurai, during the period December  2004 to  February 2006 in 
collaboration with Department of Medical Oncology, Government Rajaji 
Hospital, Madurai. 
 
The women of any age group who attended the surgical OP and presented 
with a lump in the breast were screened for Carcinoma of the breast by 
subjecting them to FNAC or Tru cut biopsy, of the lump. After confirming 
the diagnosis the patients with locally advanced breast cancer were included 
in the study group. 
 
CRITERIA FOR PATIENT SELECTION: 
INCLUSION CRITERIA: 
1. Patients with ipsilateral breast tumor in size excess of 5cm with mobile 
axillary node.  
2. Patients with ipsilateral breast tumor of any size with skin fixity. 
 were included in the study 
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EXCLUSION CRITERIA: Patients with following criteria were excluded 
from the study 
1. Bilateral breast cancer 
2. Performance status – KPS <60 (unlikely to attend the chemotherapy 
regularly )            
3. inflammatory breast cancer. 
4. tumor of any size with chest wall fixity or fixed axillary node. 
          By above mentioned inclusion and exclusion criteria 33 [thirty three]  
patients had been enrolled for the study.  All the women enrolled in the 
study were subjected to the following protocol.  They had been explained 
about the chemotherapy regimen and insisted to attend chemotherapy regime 
regularly. They had been told about surgical and radiation therapy following 
the neoadjuvant chemotherapy. 
 
      Before giving Chemotherapy the size of the tumor and the lymph node 
were  measured manually and using ultrasonogram. In both the methods the 
greatest perpendicular diameters of the lump were measured and the product 
obtained as the baseline value for the further follow up15, 18. 
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The patients were subjected to investigations like: 
Routine: 
1. Blood Hemoglobin, Total count, Differential count 
2. Blood sugar, Blood Urea, serum creatinine 
3. Liver function tests. 
4. X-ray chest PA view 
5. Echocardiogram 
6. ultrasonogram  
Some special investigations like ER/PR status and bone scan could 
not be done due to unavailability of facilities in our institution. 
After the investigations the patients were given the NEO ADJUVANT 
CHEMOTHERAPY. 
 
NEO ADJUVANT CHEMOTHERAPY REGIMEN: 
The following chemotherapy regimen was given to the patients: CAF 
INJ CYCLOPHOSPHAMIDE17, 19: an alkylating agent given as 800mg/m2 
of body surface area.  It was diluted with 500ml of dextrose solution and 
infused over 3 hours. 
INJ DOXORUBICIN17, 19: an anthracyclin antibiotic administered in the 
dose of 50mg/ m2 of the surface area.  Each 10mg was diluted with 5ml of 
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distilled water (70 mg in 35ml) and given as direct i.v over the period of 20 
mins. 
INJ 5 – FLUOROURACIL17, 19: a pyrimidine analogue administered as 
400mg/m2 it was given as direct i.v. over a period of 5 mins.                                                     
8mg of inj Ondansetron (5HT3 Antagonist) and 8mg of inj dexamethasone 
was given intravenously half an hour before chemotherapy to prevent 
vomiting.  The patient was given another dose of Ondansetron 4 hours later 
to prevent breakthrough vomiting. 
 
   Patients were subjected to the above mentioned chemotherapy regimen 
once in 21 days till maximum response was achieved or till response became 
plateau 16, 31or if patients were detected to have intolerable toxicity to the 
drugs given during chemotherapy. 
          
 Every time before the next cycle of chemotherapy was given, the 
patient was assessed for response to chemotherapy and toxicity to 
chemotherapy 
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TOXICITY OF CHEMOTHERAPY17, 19: 
   Chemotherapy is toxic to normal tissue and causes numerous significant 
side effects and complications.   Severe toxicity requires withdrawal of 
chemotherapy. The drugs used in our chemotherapy were CAF. They were 
known to produce the following toxicities.  
INJ 5-FLUOROURACIL:  when administered as bolus injection it is 
known to cause  
1. Myelosuppression 
2.  Stomatitis  
3. Diarrhoea 
4. Cerebellar ataxia 
5. Coronary vasospasm 
6. Plantar and Palmar erythema also called as hand foot syndrome. 
INJ CYCLOPHOSPHAMIDE: when given may cause 
1. Hemorrhagic cystitis 
2. Hemorrhagic myocarditis 
3. Bonemarrow suppression. 
INJ DOXORUBICIN: is associated with  
1. Cardiomyopathy consisting of intractable congestive cardiac failure,  
2. Dysrrhythmia 
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      To rule out the toxic side effects, complete hemogram and liver function 
tests were done, the patients with intractable toxicity like uncontrolled 
vomiting, myelosuppression, cerebellar ataxia, cardiomyopathy, were 
withdrawn from the chemotherapy regimen and were subjected to surgical 
intervention. Modified radical mastectomy (MRM) was done for these 
patients. 
ASSESSMENT OF CLINICAL RESPONSE15, 18, 22,23 
 
   Response to chemotherapy was assessed clinically by measuring the size 
of the tumour and lymph node manually and using ultrasonogram. The 
product of two greatest diameters were measured before each chemotherapy.  
Chemotherapy was terminated when patient achieved maximum response or 
response showed a plateau. Based on the response the patients were 
categorized into 4 groups. 
 
GROUP I  - COMPLETE CLINICAL RESPONSE: 
  Here there was no evidence of measurable tumour or new 
disease for a specified interval usually 4 weeks.  . 
GROUP II – PARTIAL CLINICAL RESPONSE:  
   Tumour size decreased 50% or more than 50% determined by 
two observations not less than 4 weeks apart. 
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GROUP III – NO RESPONSE or STABLE DISEASE 
   Tumour size decreased less than 50% 
GROUP IV – PROGRESSIVE DISEASE: 
  If 25% or greater increase was seen  in the product of one or 
more measurable lesion or appearance of new lesion, was termed 
progressive disease. 
 
For each patient the clinical response was assessed and recorded. Depending 
on the response the patients were subjected to surgery (Breast conservation 
surgery or Modified Radical Mastectomy) followed by chemotherapy and 
Radiotherapy. 
SURGICAL TREATMENT OPTION: 
1) If the clinical and radiological responses were complete breast 
conservation surgery was considered. 
2) If the response was partial and if feasible breast conservation 
surgery was done or MRM was done. 
3) In Stable or progressive disease, modified radical mastectomy 
with or without reconstruction was considered. 
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4) If the disease progressed locally with inoperability, 
preoperative radiotherapy was given followed by reassessment 
for surgery later. 
MODIFIED RADICAL MASTECTOMY (MRM) 
 For many years radical mastectomy was believed to be only appropriate 
surgical procedure for treatment of breast cancer.   Halstedian view of 
tumour biology according to which breast cancer was thought to spread in an 
orderly fashion from the site of primary tumour to axillary lymphnode then 
via lymphatics to distal sites, required  radical surgery. As time passed by it 
became apparent that distant metastasis developed in many women who 
underwent radical surgery for breast cancer, this in turn promoted  the need 
to re-examine breast cancer biology. Demonstration  of  the fact that 
moderate dose of radiation and chemotherapy successfully eradicated 
microscopic deposits of breast cancer  opened the door for use of Modified 
radical mastectomy (MRM) or Breast conservation surgeries (BCS) 
TYPES OF MRM: 
PATEY’S: It included enbloc removal of breast with axillary 
lymphatics level 1, 2, 3, and overlying skin near the tumour with 3 
to 5 cm margin.  Pectoralis major muscle was preserved, pectoralis 
minor muscle was resected. 
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AUCHINCLASS AND MADDAN’S: This was similar to Patey’s 
MRM but differed from it by preservation of the pectoralis minor 
muscle and the medial pectoral nerve and  removal of Level  1  2  
axilary node 
Procedure: 
1) Patient was positioned on the operative table in the supine 
position with rolled sheet under the ipsilateral hemithorax so as 
to allow the motion of arm without limitation.   
2) Incision was ideally made transversely from lateral border of 
sternum to just below anterior axillary fold. This incision 
included the nipple areola complex 5 cms skin around the 
lesion and the scar of the previous biopsy if any.  
3)  Skin flap was elevated in the plane between the subcutaneous 
fat and the mammary fat.  Initially cephalic flap was raised upto 
subclavius muscle.  Pectoralis fascia was dissected from 
pectoralis muscle in the plane parallel to the course of the 
muscle bundle.  Perforators of the lateral thoracic and anterior 
intercostal arteries were ligated. 
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4) Lateral flap was elevated upto anterior border of lattismus dorsi. 
5) Inferior flap was raised to upto 3 cms below inframammary 
fold. After elevating the breast from the chest wall, the breast 
was attached only to the axilla. 
6) Axillary vein was identified at lateral axillary space while 
anterior border of lattismus dorsi was dissected from inferior to 
superior direction. 
7) Shoulder was abducted and arm was extended to facilitate the 
dissection of inferior and lateral margin of pectoralis major. 
Pectoralis major was retracted to identify the pectoralis 
minor.Inter pectoral nodes were removed preserving the medial 
pectoral nerve. 
8) Loose areolar tissue at the junction of the axillary vein with the 
anterior margin of lattismus dorsi was swept inferiorly to 
include the lateral group of axillary nodes, thoraco dorsal 
vessels and nerve were preserved. Subscapular group of nodes 
between the thoraco dorsal nerve and chest wall, were dissected 
enbloc. 
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9) Central group of nodes were dissected enbloc along with 
pectoral group, and the Long thoracic nerve of Bell was 
preserved. 
10) After removal of specimen hemostasis was obtained. Two   
  vacuum drains, one for the flap and the another for the axilla   
  were inserted. 
11) Skin was sutured with subcuticular sutures. 
BREAST CONSERVATION SURGERY: 
It included terms such as wide local excision, Lumpectomy, Segmental 
mastectomy, Tylectomy.  In BCS, tumour along with one cm of normal 
tissue was removed.  The extent of surgical resection was determined by 
clinical and mammographic extent of cancer. 
 
ASSESSMENT OF PATHOLOGIC RESPONSE21:  
     Mastectomy specimens from the patients who underwent MRM were sent 
for histopathological assessment. In histo pathological examination the 
following factors were studied.  
1. The presence of tumour cells. 
2. Whether resected margins were free of tumour  
3. Status of lymph node metastasis. 
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Depending on the pathologic response the patient was categorized into 
two groups 
PATHOLOGICAL COMPLETE RESPONSE (PCR) : No tumour cells 
were detected in the resected specimen. 
PATHOLOGICAL NON RESPONDERS ( PINV) : Presence of tumour 
cells in the resected specimen. 
POST OPERATIVE RADIOTHERAPY: 
 All patients with LABC received radiotherapy of the breast or chest wall to 
a dose equivalent of 50Gy/25#/5weeks.   
ADJUVANT CHEMOTHERAPY (Total 6 cycles) : remaining cycles of 
CT completed postoperatively. 
FOLLOW UP24, 25 
In the first two years after surgery , the patients were seen atleast  once in 
every 6 months. In the following 3 years they were followed up for every 6 
to 12 months.    
  The minimum requirement for follow up were, physical examination, 
locoregional evaluation, performance scale assessment, mammography 
(done once in every 18 months) 
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    No other investigations in asymptomatic patients were performed to detect 
the metastasis, since it was not cost effective and it did not prolong the 
survival. 
    During the follow up period they were examined for the following factors,   
1. Local Recurrence 
2. Development of metastasis 
Local recurrence24, 25 : Recurrence in the post mastectomy chest wall was 
most common in the first two years, so the patient was examined for any 
nodule in the post mastectomy chestwall. 
Metastasis24,25: Patient after mastectomy go on to develop metastasis. About 
80% develop metastasis in about 5 to 10 years.  So patients during the follow 
up period need to be checked for metastasis.  Patients were enquired for 
symptoms of metastasis like bone pain, headache, dyspnea, hemoptysis, 
jaundice and seizures. 
  They were subjected to investigations like X-ray chest, Ultrasonogram of 
the liver, X- ray of the Lumbar spine, alkaline phosphatase levels, CT brain 
to rule out metastasis. 
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                      RESULTS AND DISCUSSION 
 
Table1 
 
 
 
    Stage   No. of patients  Percentage 
 
 Stage IIIA 
 
 Stage IIIB 
 
Stage IIIC 
     15 
 
     18 
 
     -- 
        45 
 
        55 
 
         -- 
               
 
 
             In the current study, after following the inclusion and exclusion 
criteria, 33 patients were enrolled, all these patients were having locally 
advanced breast cancer. Based on  the TNM stage grouping, the patients 
were categorized into 3 groups under stage III.  Out of 33 patients 15 
patients (45%) were categorized under stage IIIA.  18 patients (55%) were 
categorized under stage IIIB, There were no patients under stage IIIC.   
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Table 2 : 
Patient  
characteristics 
   Number of  
patients 
  percentage 
Age 
 
< 50 years 
 > 50 years 
 
Stage IIIA 
 Total 
 
Tumour size 
< 10cm 
>10cm 
 
Stage IIIB 
T4a 
T4b 
 
Total 
 
Axillary node status
 
No node palpable 
1 node palpable 
2 to 4 nodes 
palpable 
   
         
        27 
          6 
 
          
        15 
 
      
       12 
         3 
 
       
        -- 
       18 
 
       18 
 
 
         
        -- 
       27 
 
         6 
 
     
      81% 
     19% 
 
 
     45% 
 
 
     80% 
     20% 
 
      
     -- 
   100% 
 
     55% 
 
 
      
     -- 
    81% 
 
    19% 
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Table 2  
 The above table summarizes the patient characteristics and the clinical 
features. Out of the 33 subjects enrolled, 27 (81%) patients were less than 50 
year age group.  6 patients (19%) were aged above 50 years.  Among 15 
patients grouped under stage IIIA , 12 patients (80%) had  tumour size less 
than 10 cms.  3 patients (20%) had tumour size more than 10 cms.  Among 
the 18 patients categorized under stage IIIB, all of them had involvement of 
skin.   
       In the study group of 33 patients, all of them had palpable axillary node.  
Single node was palpable in 27 patients (81%).  Remaining 6 patients had 
axillary node status of more than one node palpable.  
Table3 
Clinical response Number of 
patients  
percentage 
Clinical complete 
response 
 
Clinical partial 
response 
 
No response or stable 
disease 
 
Progressive  
disease 
         3 
 
            
           15 
 
 
           9 
 
 
           
           6 
     9 
 
 
     46 
 
 
    27 
 
 
     
    18 
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TABLE  3: 
Evaluation of the clinical response of primary tumour and lymph node was 
one of the primary objective of study.  The product of two greatest 
perpendicular diameter was measured both manually and using 
ultrasonogram before and after every cycle of Neoadjuvant chemotherapy as 
defined by criteria. 
          The clinical response of 33 patients was observed and recorded.  Out 
of the 33 patients the overall objective clinical response of 55% was 
observed.  Complete clinical response of 9% (3 Patients) was noted.  Partial 
clinical response was noted in 15 among 33 patients (46%).  No response 
(<50% response )was observed in 9 patient (27%).  However 6 patients 
(18%) showed progressive disease.Out of the 6 patients, two of them had 
developed supraclavicular node, and 4 patients developed vertebral 
metastasis.   
           In similar studies conducted by maraz B, Boross G, Cyanti 26et al an 
over all objective response of 60%, complete clinical response of 4%, partial 
clinical response of 56% had been reported.  In their study there were no 
progressive disease observed after Neoadjuvant chemotherapy.   
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           Allassas, choq, Burton27 et al conducted a study at Lousiana state 
university health science, the complete clinical response, partial response.  
Minimal residual disease and no change was reported to be 22% , 33%, 29% 
and 15% respectively. 
Table 4: 
No. of patients with clinical 
response 
Percentage of clinical 
response 
 
Stage 
CCR CPR NR PD CCR CPR NR PD 
 
Stage IIIA 
 
Stage IIIB 
 
3 
 
 
 
6 
 
9 
 
6 
 
3 
 
 
 
6 
 
20 
 
40 
 
50 
 
40 
 
16 
 
 
 
33 
 
Table 4 
Compares clinical response of patients categorized under different groups of 
stage III.  Total of  15 patients were categorized under stage IIIA.  Among 
the 15 patients, 6 (40%) showed partial clinical response.  6 patients (40%) 
showed no response.  Complete clinical response was observed in 3 patients 
(20%).  However progressive disease was not reported in stage IIIA patients. 
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           Among the 18 patients grouped under stage IIIB, 9 patients showed 
partial clinical response 50%, no response was detected in 3 patients (16%), 
progressive disease was observed in 6 patients (33%).  There was no 
complete clinical response reported in stage IIIB patient. 
         In our study, percentage of complete response was higher for patient.  
in stage IIIA than for the patient in stage IIIB. In a similar study conducted 
by Hortobogyi, Ames and Ruzdar 28et al, in the department of Medical 
Oncology, in Anderson Hospital, Houston, it was reported that complete 
clinical response after Neoadjuvant chemotherapy was better for patient in 
stage IIIA than for patient in stage IIIB.  This correlated with the present 
study. 
Table 5. 
           The second objective in our study was to evaluate the pathological 
response of the primary tumour and lymph node to preoperative 
chemotherapy. The pathological response was classified into 2 categories, 
namely pathological complete response and PINV(invasive cells seen).  PCR 
constituted a group of patients who showed no invasive cells detected.   
          Second group consisted of patients who were termed pathological non 
responders.  (PINV), since their mastectomy specimen showed invasive cells 
on Histopathological examination. 
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          In the present study, 3 patients (9%), showed complete pathological 
response after neoadjuvant chemotherapy.  Invasive cells were detected in 
the mastectomy specimen of 30 patients on HPE (90.9%). 
TABLE 5 
 
Pathological response 
 
 
No,. of 
patients  
 
 
% of 
pathological 
response 
 
Pathological complete 
response (PCR) 
 
PINV (pathological non 
responders) 
   
  3 
 
 
    30 
   
  
 
  
 9 
 
 
  90.9 
Table 6: 
This table compares the pathological response of patient in our study group 
categorized under stage IIIA and  Stage IIIB.   
Out of the 15 patient grouped under stage IIIA, 3 patients (20%) showed 
complete pathological response and 12 patients were pathological non 
responders (80%).  However all 18 patients included under stage IIIB were 
pathologically non responders.  So in our study complete pathological 
response was not reported in stage IIIB patients. 
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TABLE 6: 
Pathological response 
 
        Percentage 
 
 
Stage 
PCR PINV PCR PINV 
 
 
Stage IIIA 
 
Stage IIIB 
 
 3 
 
 
-- 
 
 
 
12 
 
 
18 
 
 
 
20% 
 
 
-- 
 
 
 
80% 
 
 
100% 
 
 
 
Table 7  : 
Shows number of patients with resected margin free of tumour in stage IIIA 
and Stage IIIB.  There were 14 (93%) patients with resected margin free of 
tumour in stage IIIA.  Among 14patients in stage IIIB, 13(92%) were found 
to have resected margin free of tumour.  Hence over all tumour free resected 
margin of 92% was detected in our study.The remaining 4 patients in the 
stage IIIB had received radiation therapy to the vertebrae as they had 
vertebral metastasis. They did not undergo surgery 
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Table 7 
 
 
    Stage 
 
No of patients with 
resected margin free of 
tumour 
 
percentage
 
Stage IIIA 
 
Stage IIIB 
 
 
 
      14/15 
 
      13/14 
 
 
  93% 
 
  92% 
  Total 
 
       27   92% 
  
           
   A similar study conducted by Allassus, chuq, Burton27 et al, had reported 
tumour free resected margin of 92% in patients of LABC in stage III after 
neoadjuvant chemotherapy. 
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TABLE 8            
 To detect whether Neoadjuvant chemotherapy could decrease the tumour 
size there by permitting breast conservation treatment modalities was one of 
the objective of the present study.  In the study population, out of 15 patients 
categorized under stage IIIA 3 patients showed clinical complete response. 
Hence breast conservation treatment (BCT) was planned.  Since patients 
opted for mastectomy MRM was done.  
 
 
Table 8: 
 
 
    Stage  
 
Total no. of patients 
 
No. of patients planned for BCT
 
Stage IIIA 
 
 
Stage IIIB 
 
 
 
 
15 
 
 
18 
 
3 
 
 
-- 
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Table 9  summarise clinical and pathological response of each patient in the 
study group. In the present study, one of the patient in stage IIIA had 
clinically complete response, where as the pathological response showed 
invasive cells. 
 
          On the other hand one of the patient in stage IIIA in our study group 
showed clinincally detectable disease where as HPE revealed no invasive 
cells, indicating complete pathological response. 
 
 
 Zambetti , Oriana,16 et al had conducted a trial to study the clinical 
outcome of breast cancer patients with complete pathological primary 
tumour/lymph node response to adriamycin based chemotherapy.  In this 
trial, it was stated that 1/3rd of the patients with pathologically complete 
response had clinically measurable residual disease.  Conversely 1/3rd of 
patients with complete clinical response had invasive cells in their 
mastectomy specimen on HPE. 
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Table 9 
 
Stage 
 
S.No 
 
 
Clinical 
response 
 
 
Pathological
response 
 
 
Number of cycles 
 
Stage IIIA 
 
 
 
 
 
 
 
Stage IIIB 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
CCR 
CCR 
CCR 
CPR 
CPR 
CPR 
CPR 
CPR 
CPR 
CNR 
CNR 
CNR 
CNR 
CNR 
CNR 
CPR 
CPR 
CPR 
CPR 
CPR 
CPR 
CPR 
CPR 
CPR 
CNR 
CNR 
CNR 
PD 
PD 
PD 
PD 
PD 
PD 
PCR 
PCR 
PINV 
PCR 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
PINV 
-- 
-- 
-- 
-- 
4 
4 
4 
4 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
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TABLE 9            
 To detect whether Neoadjuvant chemotherapy could decrease the tumour 
size there by permitting breast conservation treatment modalities was one of 
the objective of the present study.  In the study population, out of 15 patients 
categorized under stage IIIA 3 patients showed clinical complete response. 
Hence breast conservation treatment (BCT) was planned.  Since patients 
opted for mastectomy MRM was done.  
 
Table 10: 
 
 
Response of the patient 
with metastasis to NACT 
 
Stage 
 
 
No of 
patients 
 
 
No of 
patients 
with 
metastasis 
 
 
Follow 
up 
period 
 
 
Clinical 
 
Pathological
 
Stage 
IIIA 
 
 
Stage 
IIIB 
 
15 
 
 
 
18 
 
1 
 
 
 
1 
 
15 
months 
 
 
4 
months 
 
CPR 
 
 
 
PD 
 
PINV 
 
 
 
PINV 
 
       
TABLE 10 : 
           During the follow up period, 1 patient in stage IIIA who was assessed 
to have clinical partial response/histopathologically invasive cell was 
detected to have pulmonary metastasis after a period of 15 months. 
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            Another patient categorized under stage IIIB was detected to have 
cerebral metastasis after a period of 4 months, this patient had progressive 
disease during preoperative chemotherapy and was a pathological non 
responder. 
            It was evident from the above mentioned facts in our study that 
patients who had a complete clinical response, had a comparably good 
prognosis than those patients who showed a partial or no response to 
neoadjuvant chemotherapy. 
            Y.W. Moon Rha 30et al in their study showed that those patients with 
a good response to neoadjuvant chemotherapy had a good prognosis. Gajdas 
and Tarttar29et al had concluded in their study, that patients with a complete 
pathological and clinical response were observed to have good prognosis 
than those patients with partial or no clinical response and than those who 
had invasive cells on HPE of their resected specimen. 
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                                      CONCLUSION 
 
 
From this study it was evident that neoadjuvant chemotherapy could  
1) Downstage the disease so as to make the inoperable tumour to  
operable one and to plan breast conservation for operable disease. 
2) Patients who did not respond to NACT or who showed disease 
progression during NACT were predicted to have poor prognosis 
compared to those who had shown objective response to neoadjuvant 
chemotherapy. 
3) NACT also made it possible to resect locally advanced disease with 
tumour free margin in most cases (92%) 
  
 Thus NACT plays an important role in clinical trials as it allows more 
rapid comparison of treatment regimes than can be accomplished in the 
adjuvant settings.  It also provides an opportunity to analyze biological 
markers as predictors of response to CT. 
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ABBREVIATIONS 
 
LABC    – Locally advanced breast cancer 
 
NACT   – Neoadjuvant chemotherapy 
 
MRM    – Modified radical mastectomy 
 
BCS      – Breast conservation surgery 
 
BCT      – Breast conservation treatment 
 
CCR      – Clinical complete response 
 
CPR      – Clinical Partial response 
 
CNR     – Clinical No response 
 
PD        – Progressive disease 
 
PCR      – Pathological complete response 
 
PINV    – Pathologically invasive cells 
 
CT        – chemotherapy 
 
RT        – Radiotherapy 
 
AJCC   – American Joint committee on cancer 
 
UICC – International union against cancer 
  
P 
PROFORMA FOR ROLE OF NEOADJUVANT CHEMOTHERAPY IN 
LOCALLY ADVANCED  BREAST CANCER 
 
NAME:                  AGE:                       SEX:                                 I.P.NO 
 
 
ADDRESS:                                        HEIGHT:                  WEIGHT: 
 
 
 
 
 
 
CLINICAL EXAMINATION: 
 
 
CLINICAL STAGING: 
 
 
INVESTIGATION: 
 
a) FNAC/TRU CUT BIOPSY 
b) BLOOD Hb 
c) BLOOD UREA 
d) BLOOD SUGAR 
e) SERUM CREATININE 
f) LFT: SERUM BILIRUBIN  
g) SERUM ALKALINE PHOSPHATASE 
h) SGOT 
i) SGPT 
j) X-RAY CHEST PA VIEW 
k) ULTRASONOGRAM ABDOMEN 
l) ECHOCARDIOGRAM 
  
 
MEDICAL ONCOLOGIST OPINION: 
 
CHEMOTHERAPY: 
 
Number Date 
 
Breast 
lump size 
 Lymph Node size Response % 
Ist cycle     
2nd cycle     
3rd cycle     
4th cycle     
5th cycle     
6th cycle     
 
 
CLINICAL RESPONSE: CCR/CPR/CNR/PD 
 
TREATMENT GIVEN: 
 
SURGERY: WIDE LOCAL EXCISION WITH AXILLARY DISSECTION / MRM 
 
ADJUVANT CHEMOTHERAPY: 
 
RADIOTHERAPY: 
 
HARMONAL THERAPY: 
 
POSTOPERATIVE BIOPSY REPORT: 
 
PATHOLOGICAL RESPONSE: PCR/PINV 
 
 
FOLLOW UP : 
STAGE WISE CLASSIFICATION OF 
PATIENTS 
45%
55%
 Stage IIIA
 Stage IIIB
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 <50 >50
Age
 <10 >10 
Tumor Size
 <1 >1   
Node
PATIENTS CHARACTERISTICS
 
 
CLINICAL RESPONSE
9%
46%27%
18%
Clinical complete response Clinical partial response
No response or stable disease Progressive disease
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COMPARISION OF CLINICAL RESPONSE
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PATHOLOGICAL RESPONSE
9%
91%
Pathological complete response (PCR)
PINV (pathological non responders)
 
 
 
 
 
20%
80%
0
100%
0%
20%
40%
60%
80%
100%
PE
RC
EN
TA
G
E
Stage IIIA Stage III B
COMPARISION OF PATHOLOGICAL 
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PCR PINV
 
 
RESECTED MARGIN FREE OF TUMOR 
CELLS
8%
92%
Margin Positive Margin Negative
 
 
 
 
 
PLAN OF TREATMENT
26
3
4
PLANNED MRM PLANNED BCS NO SURGICAL INTERVENTION
 
 
S.No NAME AGE I.P.No
STAGE      
GROUPING 
NO OF CYCLES   
OF NACT
CLINICAL      
RESPONSE
PATHOLOGICAL 
RESPONSE SURGERY DONE FOLLOW UP
1 Panchavarnam 45 343866 Stage III A 4 CCR PINV MRM No Locoregional recurrence or metastasis
2 Pappa 45 393663 Stage III A 3 CNR PINV MRM No Locoregional recurrence or metastasis
3 Kala 32 363612 Stage III A 3 CNR PINV MRM No Locoregional recurrence or metastasis
4 Pandiammal 40 356799 Stage III A 3 CPR PINV MRM No Locoregional recurrence or metastasis
5 Kangalakshmi 40 294960 Stage III A 4 CPR PCR MRM No Locoregional recurrence or metastasis
6 Oyyammal 45 390042 Stage III A 3 CCR PCR MRM No Locoregional recurrence or metastasis
7 Amina 42 294072 Stage III A 3 CCR PCR MRM No Locoregional recurrence or metastasis
8 Rabha 50 372672 Stage III A 3 CNR PINV MRM No Locoregional recurrence or metastasis
9 Kanagam 49 412721 Stage III A 3 CPR PINV MRM No Locoregional recurrence or metastasis
10 Ramayee 45 402242 Stage III A 3 CPR PINV MRM No Locoregional recurrence or metastasis
11 Amirtham 47 384219 Stage III A 3 CNR PINV MRM No Locoregional recurrence or metastasis
12 Selvi 50 414120 Stage III A 3 CNR PINV MRM No Locoregional recurrence or metastasis
13 Archana 49 424162 Stage III A 3 CPR PINV MRM No Locoregional recurrence or metastasis
14 Karthika 47 384271 Stage III A 3 CPR PINV MRM No Locoregional recurrence or metastasis
15 Rani 46 387992 Stage III A 3 CNR PINV MRM No Locoregional recurrence or metastasis
16 Chinnammal 60 344344 Stage III B 3 PD PINV MRM Cerebral etastasis after 4 months
17 Palaniammal 30 297138 Stage III B 3 CPR PINV MRM Pulmonary metastasis after 15 months
18 Selvi 50 377370 Stage III B 3 CNR PINV MRM No Locoregional recurrence or metastasis
19 Algammal 45 360684 Stage III B 3 PD - Pateints received RT to vertebral metastasis
20 Irulayee 65 243293 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
21 Meenakshi 40 345607 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
22 Karupayee 60 298071 Stage III B 3 CNR PINV MRM No Locoregional recurrence or metastasis
23 Backyalaksmi 42 394216 Stage III B 3 PD - Pateints received RT to vertebral metastasis Pateints received RT to vertebral metastasis
24 Jayanthi 47 421672 Stage III B 3 CNR PINV MRM No Locoregional recurrence or metastasis
25 Prema 45 407216 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
26 Shanthi 50 396086 Stage III B 3 PD PINV MRM No Locoregional recurrence or metastasis
27 Parameshwari 49 400423 Stage III B 3 PD - Pateints received RT to vertebral metastasis
28 Pandeswari 62 400262 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
29 Murugalakshmi 46 420011 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
30 Rajeswari 47 416680 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
31 Muniammal 48 306072 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
32 Chinnathai 61 367200 Stage III B 3 CPR PINV MRM No Locoregional recurrence or metastasis
MASTER CHART
33 Jeevarathinam 62 421021 Stage III B 3 PD - Pateints received RT to vertebral metastasis
